Article

Study recommends 4-year screening interval for PCa

Author(s):

Cheryl Guttman Krader, BS, Pharm

Rotterdam, Netherlands-Four years is a reasonable interval for prostatecancer screening, concluded investigators from the European Randomized Studyof Screening for Prostate Cancer (ERSPC).

Related Videos
Adam Weiner, MD, on therapeutic decision-making in metastatic prostate cancer
Adam Weiner, MD, on therapeutic decision-making in metastatic prostate cancer
3 experts are featured in this series.
Real-World Safety of Androgen Receptor Inhibitors in Nonmetastatic Castration-Resistant Prostate Cancer
Fred Saad, MD, FRCP, reacts to FDA approval of darolutamide in mCSPC
Fred Saad, MD, FRCP, reacts to FDA approval of darolutamide in mCSPC
1 expert is featured in this series.
The Role of Bone-Targeted Therapies
Topline Results From Recent NMIBC Trials
Topline Results From Recent NMIBC Trials
Exploring Nadofaragene Firadenovec: Ongoing Trials and Study Designs
Exploring Nadofaragene Firadenovec: Ongoing Trials and Study Designs
1 expert is featured in this series.
First-Line mHSPC Therapy: AR Inhibitors vs Chemotherapy
Professor Dickon Hayne shares data on mitomycin plus BCG in high-risk NMIBC
Professor Dickon Hayne shares data on mitomycin plus BCG in high-risk NMIBC
Thomas Powles, MBBS, MRCP, MD, on efficacy of sasanlimab plus BCG in BCG-naïve NMIBC
Thomas Powles, MBBS, MRCP, MD, on efficacy of sasanlimab plus BCG in BCG-naïve NMIBC
1 expert in this video
Using Ultrasensitive PSA Assays in Routine Practice
Related Content
Human kidney cross section on scientific background | Image Credit: © Crystal light - stock.adobe.com
June 5th 2025

Sintilimab plus fruquintinib under review in China for advanced renal cell carcinoma

Hannah Clarke
The new drug application is backed by data from the phase 2/3 FRUSICA-2 trial.
Pearls & Perspectives: Understanding and Improving Pelvic Health, with Diane Newman, DNP
June 2nd 2025

Pearls & Perspectives: Understanding and Improving Pelvic Health, with Diane Newman, DNP

Amy M. Pearlman, MD
Jad Chahoud, MD, MPH
June 5th 2025

Zanzalintinib plus nivolumab shows safety, efficacy for stage 4 RCC

Benjamin P. Saylor
ORR in the zanzalintinib plus nivolumab arm was 63% (95% CI: 46-77) vs 40% (95% CI: 25-57) in the zanzalintinib plus nivolumab/relatlimab arm.
Pearls & Perspectives: From Guidelines to Practice—Navigating the TRT Treatment Spectrum, with Alex Tatem, MD
May 17th 2025

Pearls & Perspectives: From Guidelines to Practice—Navigating the TRT Treatment Spectrum, with Alex Tatem, MD

Amy M. Pearlman, MD Alex Tatem, MD
Explore the latest insights on testosterone therapy, its benefits, and practical applications from leading urologists in men's health.
Neal D. Shore, MD, FACS
June 4th 2025

How immunotherapy and trials are redefining the treatment of bladder cancer

Urology Times staff
The Clinical Forum underscored the importance of clinical trials and multidisciplinary collaboration in advancing bladder cancer care.
Adding niraparib to AAP extends rPFS in HRR-positive mCSPC
June 4th 2025

Adding niraparib to AAP extends rPFS in HRR-positive mCSPC

Hannah Clarke
“AMPLITUDE supports early genomic testing and niraparib plus AAP as a new treatment option for patients with mCSPC and HRR gene alterations," the authors wrote.
© 2025 MJH Life Sciences

All rights reserved.